A 48-Year-Old Man With Recurrent Nasopharyngeal Carcinoma and a 53-Year-Old Woman With Metastatic Nasopharyngeal Carcinoma

An expert discusses the use of toripalimab in the treatment of recurrent and metastatic nasopharyngeal carcinoma (NPC) through clinical case introductions.

An expert discusses key considerations for nasopharyngeal carcinoma (NPC) therapy from the perspective of radiation oncology.

An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for re-irradiation, while also reflecting on the treatment strategy in Case 2 and the criteria for determining whether the patient would benefit from additional radiation therapy.

An expert discusses strategies for monitoring response to treatment, including observation, Epstein-Barr virus (EBV) titers, and other relevant methods.

An expert discusses emerging developments in the use of systemic immunotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC) from the perspective of a radiation oncologist, highlighting how findings from Liu et al (Lancet, 2024) inform the evolving treatment landscape.